Skip to Content

Pirtobrutinib Outperforms Investigators’ Choice in Relapsed/Refractory CLL After BTK Inhibitor Therapy

At ASH 2024, Professor Paolo Ghia discusses the BRUIN CLL-321 phase 3 trial, which demonstrates the efficacy of pirtobrutinib, a non-covalent BTK inhibitor, in patients with relapsed/refractory CLL who previously received covalent BTK inhibitors. The study shows prolonged progression-free survival and manageable side effects and is the first study to address this patient population in a relapsed/refractory setting.

Paolo Ghia

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top